Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Foundation Medicine CDx, Bayer's Vitrakvi for NTRK Patients

NEW YORK – Foundation Medicine announced on Friday its FoundationOne CDx test received approval from the US Food and Drug Administration for use with larotrectinib (Bayer's Vitrakvi) to help identify cancer patients with neurotrophic receptor tyrosine kinase fusions. 

Foundation's comprehensive genomic profiling test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with select rearrangements and genomic signatures across all solid tumors. Those signatures include the three NTRK gene fusions, which are more commonly found in rare cancer types such as secretory carcinoma of the breast, Foundation said in a statement. The test is approved as a companion diagnostic for more than 20 therapies, the company added. The Roche subsidiary said the approval is part of a collaboration between Bayer and Foundation Medicine to develop and commercialize next-generation sequencing-based companion diagnostics in oncology. 

Larotrectinib is approved in the US for refractory patients with TRK fusion-positive solid tumors who don't have a known acquired resistance mutation. It is approved for patients who are metastatic, or in cases where surgical resection is "likely to result in severe morbidity," Bayer said.

Chugai Pharmaceuticals, a Foundation Medicine partner in Japan, filed an application with the Japanese Ministry of Health, Labour, and Welfare for expanded use of FoundationOne CDx with larotrectinib, Bayer said.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.